

## Cell Line Data Sheet for LA-N-5

**Disease:** Neuroblastoma  
**Phase of Therapy:** Diagnosis  
**Treatment:** None  
**Disease Stage:**  
**Gender:** Male  
**Age at diagnosis:** 5 months  
**Race:** N/A  
**Age at sample collection:** N/A  
**Source of Culture:** Bone Marrow  
**Primary Tumor Site:** N/A  
**Date Established:** N/A

**MYCN Patient:** Amplified  
**MYCN Cell line:** N/A  
**TH mRNA:** Positive  
**p53 functionality:** N/A  
**Telomere Mechanism** N/A  
**ALK:** R1275Q

**IC90 (DIMSCAN\*):** CBDCA (µg/ml) CDDP (µg/ml) DOX (ng/ml) ETOP (ng/ml) L-PAM (µg/ml)  
 \*see reference 4 N/A N/A N/A N/A N/A  
 CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan

**Growth Conditions:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
 5% CO<sub>2</sub>, 20% O<sub>2</sub>, 37.0°C

**Media Formulation:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

**Doubling Time:** 100 hours  
**Growth Properties:** Teardrop-shaped cells with processes, adherent, grow mostly in clusters

**STR Profile:** May be obtained at <https://strdb.cccells.org/>

### Notes:

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



---

## Cell Line Data Sheet for LA-N-5

---

### References:

1. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. *Prog Clin Biol Res.* 271:291-306, 1988. PubMed ID: 3406003  
<https://pubmed.ncbi.nlm.nih.gov/3406003/>
2. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of Protein Gene Product 9.5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors. *Clin Cancer Res.* 6, 551-558, 2000. PubMed ID: 10690538  
<https://clincancerres.aacrjournals.org/content/6/2/551.long>
3. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. *Cancer Res.* 61, 679-686, 2001. PubMed ID: 11212268  
<https://cancerres.aacrjournals.org/content/61/2/679.long>
4. Frgala T, Kalous O, Proffitt RT, Reynolds CP: A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. *Mol Cancer Ther.* 6:886-89, 2007. PubMed ID: 17363483  
<https://mct.aacrjournals.org/content/6/3/886.long>
5. Thiele, Carol J., McKeon, Catherine, Triche, Timothy J., Ross, Robert A., Reynolds, C. Patrick, and Israel, Mark A. (1987). Differential Protooncogene Expression Characterizes Histopathologically Indistinguishable Tumors of the Peripheral Nervous System. *J Clin Invest* 80: 804-811. PubMed ID: 2887586  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442306/>
6. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer.* 56: 239-249, 2011. PubMed ID: 20922763 ([www.PPTPinvitro.org](http://www.PPTPinvitro.org))  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>
7. J. L. Harenza, M. A. Diamond, R. N. Adams, M. M. Song, H. L. Davidson, L. S. Hart, M. H. Dent, P. Fortina, C. P. Reynolds, J. M. Maris, Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. *Sci Data.* 2017;4:170033. PMID: 28350380  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369315/>



---

## Cell Line Data Sheet for LA-N-5

---

**Cell Line Name:** LA-N-5

**Low confluency (10x magnification)**

**High confluency (10x magnification)**

**Low confluency (20x magnification)**

**High confluency (20x magnification)**